Cipla reported INR434.34B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Arca Biopharma USD 1.23B 91.63M Sep/2026
aTyr Pharma USD 59.81M 10.02M Sep/2026
Bio Path USD 677K 13K Mar/2026
Brainstorm Cell Therapeutics USD 788K 33K Jun/2026
Capricor Therapeutics USD 330.37M 38.37M Sep/2026
Cara Therapeutics USD 23.53M 2.28M Sep/2026
Cipla INR 434.34B 9.38B Sep/2026
Dr.Reddys Laboratories INR 576.31B 1.01B Sep/2026
Immunic USD 136.42M 22.75M Sep/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sun Pharmaceuticals INR 1.15T 60.53B Sep/2026
TherapeuticsMD USD 40.13M 1.96M Jun/2024
UPL INR 1.01T 58.17B Sep/2026